Daclatasvir 60 mg

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Hospital do Coracao

Conditions

COVID-19Hepatitis CHepatitis C VirusKidney Failure, Chronic

Phase 2

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

CompletedNCT02349048

Janssen Research & Development, LLCHepatitis C Virus

Start: 2015-01-31End: 2016-05-31Updated: 2017-03-01

Antiviral Agents Against COVID-19 Infection

CompletedNCT04468087

Hospital do CoracaoCOVID-19

Start: 2021-02-15End: 2021-08-04Updated: 2024-03-22

Phase 3

Safety of Sofosbuvir in People With Advanced Kidney Failure

CompletedNCT03883698

Sanjay Gandhi Postgraduate Institute of Medical SciencesHepatitis C, Kidney Failure, Chronic

Start: 2019-03-15End: 2020-08-01Updated: 2021-04-06

Related Papers

Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX - REVOLUTIOn trial.

2023-03-084 citations

Antivirais para pacientes adultos hospitalizados com infecção por SARS-CoV-2: Um estudo de Fase II/III, randomizado, multicêntrico, controlado por placebo, adaptativo, commúltiplosbraçoseestágios. COALITION COVID-19 BRAZIL IX – REVOLUTIOn: protocolo e plano de análise estatística

Revista Brasileira de Terapia Intensiva2022-01-011 citations

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for <scp>HCV</scp> genotype 1 infection

Journal of Viral Hepatitis2017-12-2412 citations